Callio Therapeutics has raised $187m in a Series A financing round to achieve clinical proof-of-concept for its human epidermal growth factor receptor 2-targeted dual-payload antibody-drug conjugate ...
Frazier Life Sciences has launched Callio Therapeutics with $187 million in series A funds and a HER2-targeted dual-payload antibody-drug conjugate that’s ready for the clinic. The ADC, and Callio’s ...
Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience Financing ...
Biotech-focused investment firm Frazier Life Sciences has launched Callio Therapeutics, a cancer treatment startup with headquarters in Seattle and Singapore. Frazier led a $187 million Series A round ...
At a time when skateboarding footwear is kind of a free-for-all (well, except for the mighty giants—you know the ones), Hours Is Yours continues to keep things sleek, stylish and skate-ready. But what ...
Rick: Would you give $187 million to a company still looking to achieve proof of concept? That's exactly what a group of investors did with Callio Therapeutics, which you can read about below. What ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results